Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Pharmacologic Substance > Antiplatelet Agents

Antiplatelet Agents

Antiplatelet agents are a class of drugs that inhibit platelet aggregation and thrombosis, thereby reducing the risk of cardiovascular events.
These medications play a crucial role in the management of various conditions, such as coronary artery disease, ischemic stroke, and peripheral artery disease.
PubCompare.ai's AI-driven platform can help researchers optimize their studies on antiplatelet agents by effortlessly locating and comparing protocols from literature, pre-prints, and patents.
This advanced solution allows users to identify the best protocols and products to accelerate their research, streamlining the process and enhancing productivity.

Most cited protocols related to «Antiplatelet Agents»

1
Validating AMI Diagnosis Accuracy
The matching rate was presented as the number of matched cases divided by the number of cases retrieved from the DNMC (the gold standard). The validity of using the ICD-9 410.xx code to identify matched cases of AMI was assessed by calculating the positive predictive value (PPV) using medical records (of confirmed cases after review by the cardiologists) as the gold standard. The agreement rate between the two reviewers was calculated using the agreement cases divided by the total cases. In addition, we estimated the PPV of principal diagnosis, antiplatelet therapy, and cardiac procedures of confirmed AMI cases. Further, different criteria were used to evaluate sensitivity and PPV of the diagnosis code of AMI in the NHIRD, such as “principal diagnosis with antiplatelet” or “principal diagnosis with percutaneous transluminal coronary angioplasty (PTCA)”.
To ensure validity of procedures and aspirin/clopidogrel exposure, we defined sensitivity as the probability that the procedure/antiplatelet agents recorded in the medical chart (denominator) by a doctor were also recorded in the NHIRD (numerator). PPV is the conditional probability that claims of procedures/antiplatelet agents in the NHIRD (denominator) were actually present in the DNMC records (numerator). For agreement among discharge diagnoses for each AMI hospitalization, percentage of consistency between the two databases was calculated for linkage cases.
All computations and 95% confidence intervals (CIs) for binominal proportions were performed with SAS version 9.2 (SAS Institute Inc, Cary, NC, USA). This study was reviewed and approved by the Institutional Review Board of the National Cheng Kung University Medical Center (ER-95-137).
Cheng C.L., Lee C.H., Chen P.S., Li Y.H., Lin S.J, & Yang Y.H. (2014). Validation of Acute Myocardial Infarction Cases in the National Health Insurance Research Database in Taiwan. Journal of Epidemiology, 24(6), 500-507.
Full text: Click here
Publication 2014
Antiplatelet Agents Aspirin Cardiologists Clopidogrel Diagnosis Ethics Committees, Research Gold Heart Hospitalization Hypersensitivity Patient Discharge Percutaneous Transluminal Coronary Angioplasty Physicians Therapeutics
2
Thromboembolism Risk in Non-Valvular Atrial Fibrillation
In patients discharged with non-valvular atrial fibrillation who were not receiving treatment with vitamin K antagonists or heparins, we estimated event rates for thromboembolism and death for the various CHADS2 and CHA2DS2-VASc scores and for the specific covariate combinations forming the scores of 1 or 2. We estimated the risk of thromboembolism by using Cox proportional hazard regression models. In the Cox models, we analysed the risk associated with all possible risk factor combinations for CHADS2 score=1 (four combinations) and CHADS2 score=2 (seven combinations); we used CHADS2 score=0 as the reference. In the same manner, other Cox models analysed the risk associated with all possible risk factor combinations for CHA2DS2-VASc score=1 (six combinations) and CHA2DS2-VASc score=2 (17 combinations), with CHA2DS2-VASc score=0 used as the reference. We did all analyses for one, five, and 10 years of follow-up. In additional Cox regression models, we included concomitant treatment with antiplatelet drugs (that is, primary acetylsalicylic acid, clopidogrel, and dipyridamole), to adjust for this potential confounder. We also did sensitivity analyses by not including pulmonary embolism as an outcome.
We used C statistics estimated from Cox regression models to assess the predictive capability of CHADS2 and CHA2DS2-VASc for thromboembolism, using the method described by Liu and colleagues.24 C statistics give a measure of how well the risk prediction scheme identifies patients who will have a future event. For estimating C statistics, we analysed CHADS2 and CHA2DS2-VASc as risk scores (0-6 and 0-9) and as risk groups (low, intermediate, and high). We also evaluated the scores both as categorical and as continuous covariates. We constructed survival curves, based on Kaplan-Meier estimates of the probability of remaining free of thromboembolism with a score of 0 and 1, for the two risk stratification schemes. We considered a two sided P value <0.05 to be statistically significant. In all Cox models, the model assumptions (that is, proportional hazards, linearity of continuous covariates, and lack of interactions) were found to be valid. We used SAS statistical software version 9.1 and Stata statistical software version 11.0 for the analyses.
Olesen J.B., Lip G.Y., Hansen M.L., Hansen P.R., Tolstrup J.S., Lindhardsen J., Selmer C., Ahlehoff O., Olsen A.M., Gislason G.H, & Torp-Pedersen C. (2011). Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. The BMJ, 342, d124.
Publication 2011
antagonists Antiplatelet Agents Aspirin Atrial Fibrillation Clopidogrel Dipyridamole Heparin Hypersensitivity Patients Population at Risk Pulmonary Embolism Thromboembolism Vitamin K
3
Aspirin for Primary and Secondary Prevention

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Antiplatelet Agents Aspirin Cerebrovascular Accident Myocardial Infarction N-acetyl-S-(alpha-methyl-4-(2-methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl ester Primary Prevention Secondary Prevention Transient Ischemic Attack Vascular Diseases
4
Platelet Activation Assay for Vaccine-Induced Thrombosis
We purified platelets from whole blood (obtained from healthy volunteers) that had undergone anticoagulation with adenine citrate dextrose solution A. None of the volunteers had been taking antiplatelet drugs or had been vaccinated in the previous 10 days. We prepared platelets using methods that have been described previously.2 (link),3 (link) In a subgroup of experiments, platelets were preincubated in buffer with ChAdOx1 nCov-19 (1:2000 dilution) and washed before use. Washed platelets (75 microliters) were incubated with either buffer, a low-molecular-weight heparin (reviparin [Abbott]), or PF4 (Chromatec) in either the presence or absence of the FcγIIa receptor–blocking antibody IV.3. In some experiments, unfractionated heparin (100 IU per milliliter) was added to inhibit PF4-dependent reactions, or ChAdOx1 nCov-19 (1:50 dilution) was added per well. Serum was coincubated with PF4 and platelets in the presence of immune globulin (Privigen IVIG [CSL Behring]) at a concentration of 10 mg per milliliter. After establishing assay conditions using serum from the initial four patients, we investigated another 24 serum samples that tested positive on immunoassay to validate our findings. We refer to this modified platelet-activation test as the PF4-enhanced platelet-activation test.
To measure direct antibody binding, we used two immunoassays, a PF4–heparin enzyme-linked immunosorbent assay (ELISA) and a PF4 ELISA, with antibody binding measured by a secondary antihuman IgG, as described previously.4 (link) In addition, antibodies from two serum samples were affinity purified by immobilized PF4–heparin and immobilized PF4, and the purified antibodies were tested in the assays. (Details about this method are provided in the Supplementary Appendix, available with the full text of this article at NEJM.org.)
We defined reactivity on ELISA according to the optical-density units as strong (≥2.00), intermediate (1.00 to 1.99), or weak (0.50 to 0.99). On the PF4-enhanced platelet-activation test, reactivity was graded according to the time that had elapsed until platelet aggregation,5 (link) with shorter reaction times indicating stronger platelet activation (strong activation, 1 to 5 minutes; intermediate activation, >5 to 15 minutes; and weak activation, >15 to 30 minutes).
Greinacher A., Thiele T., Warkentin T.E., Weisser K., Kyrle P.A, & Eichinger S. (2021). Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. The New England Journal of Medicine.
Publication 2021
Adenine Antibodies Antibodies, Blocking Antiplatelet Agents Biological Assay Blood Platelets Buffers Cardiac Arrest ChAdOx1 nCoV-19 Citrates Debility Enzyme-Linked Immunosorbent Assay Glucose Healthy Volunteers Heparin Heparin, Low-Molecular-Weight Immunoassay Immunoglobulins Intravenous Immunoglobulins Patients Platelet Activation Platelet Aggregation Privigen reviparin Serum Technique, Dilution Voluntary Workers
5
Aspirin for Primary Prevention in Older Adults
Eligible participants were community-dwelling adults from Australia and the United States who were 70 years of age or older (or ≥65 years of age among blacks and Hispanics in the United States). Eligibility criteria are provided in Table S1 in the Supplementary Appendix, available at NEJM.org. Participants were required to be free from overt coronary heart disease, overt cerebrovascular disease, atrial fibrillation, a clinical diagnosis of dementia, clinically significant physical disability, a high risk of bleeding, anemia, and a known contraindication to or inability to take aspirin. Key exclusion criteria were the current regular use of an anticoagulant or antiplatelet medication other than aspirin, a systolic blood pressure of 180 mm Hg or more or a diastolic blood pressure of 105 mm Hg or more, a medical indication for or contraindication to regular aspirin therapy, or the presence of a condition that, in the opinion of the primary care physician, was likely to result in death within 5 years. Participants were allowed to take other nonsteroidal antiinflammatory drugs (NSAIDs), with the recommendation to take the lowest dose for the shortest duration necessary.
McNeil J.J., Wolfe R., Woods R.L., Tonkin A.M., Donnan G.A., Nelson M.R., Reid C.M., Lockery J.E., Kirpach B., Storey E., Shah R.C., Williamson J.D., Margolis K.L., Ernst M.E., Abhayaratna W.P., Stocks N., Fitzgerald S.M., Orchard S.G., Trevaks R.E., Beilin L.J., Johnston C.I., Ryan J., Radziszewska B., Jelinek M., Malik M., Eaton C.B., Brauer D., Cloud G., Wood E.M., Mahady S.E., Satterfield S., Grimm R, & Murray A.M. (2018). Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. The New England journal of medicine, 379(16), 1509-1518.
Publication 2018
Adult Anemia Anti-Inflammatory Agents, Non-Steroidal Anticoagulants Antiplatelet Agents Aspirin Atrial Fibrillation Cerebrovascular Disorders Dementia Diagnosis Disabled Persons Eligibility Determination Heart Disease, Coronary Hispanics Negroes Pharmaceutical Preparations Physical Examination Pressure, Diastolic Primary Care Physicians Systolic Pressure Therapeutics

Most recents protocols related to «Antiplatelet Agents»

1
Baseline Characteristics of CKD Patients
Baseline characteristics were recorded by clinical research associates from medical files or by interview. Data included age, sex, body mass index (BMI), hypertension (patients having an office blood pressure greater than or equal to 140/90 mmHg or an antihypertensive treatment), cardiovascular history (coronary artery disease, arrhythmic disorders, congestive heart failure, stroke, peripheral vascular disease and/or valvulopathy), diabetes (diabetes history or antidiabetic treatment or glycated hemoglobin ≥ 6.5% or fasting glycemia ≥ 7 mmol/l or non-fasting glycemia ≥ 11), gout history, dyslipidemia, primary kidney disease, time since CKD diagnosis (time elapsed from the date of CKD diagnosis found in the medical record and the cohort entry), number of consultation in the previous year with nephrologist and dietician, treatment (urate-lowering therapy (ULT), diuretics, antiplatelet agents, renin-angiotensin system inhibitors (RASi)), laboratory data (serum creatinine, eGFR estimated by the CKD-EPI equation, serum UA, albuminemia, C-reactive protein and, albuminuria—or equivalent—classified according to the KDIGO 2012 guidelines16 ), salt intake (estimated by 24-h natriuresis) and protein intake (estimated by 24-h urinary urea)17 (link), medication adherence according to the Girerd score in categories (good, minimal and poor)18 (link), health literacy according to their need for help reading medical documents (never need vs always or partly need)19 (link) and type of center (university, non-university hospital, private non-profit and private for-profit clinic).
Prezelin-Reydit M., Combe C., Fouque D., Frimat L., Jacquelinet C., Laville M., Massy Z.A., Lange C., Ayav C., Pecoits-Filho R., Liabeuf S., Stengel B., Harambat J, & Leffondré K. (2023). Longitudinal uric acid has nonlinear association with kidney failure and mortality in chronic kidney disease. Scientific Reports, 13, 3952.
Full text: Click here
Publication 2023
Antidiabetics Antihypertensive Agents Antiplatelet Agents Blood Pressure Cardiovascular System Cerebrovascular Accident Congestive Heart Failure Coronary Artery Disease C Reactive Protein Creatinine Diabetes Mellitus Diagnosis Dietitian Diuretics Dyslipidemias EGFR protein, human Gout Health Literacy Hemoglobin, Glycosylated High Blood Pressures Index, Body Mass inhibitors Kidney Diseases Natriuresis Nephrologists Patients Peripheral Vascular Diseases Proteins Serum Sodium Chloride, Dietary System, Renin-Angiotensin Therapeutics Urate Urea Urine Valve Disease, Heart
2
Cognitive Resilience in Alzheimer's Disease

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Abuse, Alcohol Alzheimer's Disease Amyloid angiopathy Anticoagulants Antihypertensive Agents Antiplatelet Agents ApoE protein, human Cardiac Arrest Cerebrovascular Accident Cognition Congestive Heart Failure Diabetes Mellitus Family Member Hemorrhage High Blood Pressures Hippocampal Sclerosis Hypercholesterolemia Index, Body Mass Infarction, Lacunar Lewy Bodies Myocardial Infarction Neurofibrillary Tangle Pharmaceutical Preparations Respiratory Diaphragm Senile Plaques Thyroid Diseases Transient Ischemic Attack
3
Emergent Laparotomy for Intestinal Resection
Patients underwent emergent laparotomy under general anesthesia. The periods between definite diagnosis (by contrast CT scan) and surgery were measured. Operative factors included combined colon resection, end-enterostomy or reanastomosis, length of functional residual small intestine (length between the Treitz ligament and the end-enterostomy or ileocecal area), and blood transfusion. Both postoperative anticoagulant agents and postoperative antiplatelet agents were recorded. Postoperative mortality was defined as death after intestinal resection. The periods between intestinal resection and death were measured. The 30-day mortality was analyzed for short-term results. The prognosis was revealed by the survival curve.
Liu H.T., Lai C.Y., Liao J.J., Chen Y.J., Cheng S.B, & Wu C.C. (2023). Immediate postoperative parenteral anticoagulant therapy in patients with mesenteric ischemia after intestinal resection: a retrospective cohort study at a single institute. BMC Gastroenterology, 23, 56.
Full text: Click here
Publication 2023
Anticoagulants Antiplatelet Agents Blood Transfusion Colon Diagnosis Enterostomy General Anesthesia Intestines Intestines, Small Laparotomy Ligaments Operative Surgical Procedures Patients Prognosis X-Ray Computed Tomography
4
Cardiovascular Risk Factors in Atrial Fibrillation
Age, sex, co-morbidities including hypertension, diabetes, dyslipidemia, heart failure, prior stroke, prior myocardial infarction, peripheral artery disease, chronic kidney disease, chronic obstructive pulmonary disease (COPD), and cancer, CHA2DS2-VASc score, Charlson Comorbidity Index (CCI), and concomitant use of antiplatelet agents were evaluated as covariates. The operational definitions of co-morbidities were based on diagnostic codes, drug dispensing records, and inpatient/outpatient hospital visits within 3 years prior to the index date. Complete definitions of each covariate are presented in Supplementary Tables S1 and S2 (5 (link), 15 (link), 16 (link)).
Among the total study population, 67.4% of patients had the data from the baseline national health examination, and 23.4% had the data from both baseline and at least one follow-up national health examination. From the health examination data, body weight, body mass index (kg/m2), serum creatinine (mg/dL) and eGFR (mL/min/1.73 m2) were collected. eGFR was calculated by a creatinine-based equation used from Modification of Diet in Renal Disease. In addition, smoking status (never smoker, ex-smoker, or current smoker), alcohol consumption (heavy drinker, ≥ 30 g/day), and physical activity were also evaluated from the self-reported questionnaires of health examination. Regular exercise was defined as performing moderate-intensity exercise ≥ 5 times per week or vigorous-intensity exercise ≥ 3 times per week (17 (link)).
Lee S.R., Choi E.K., Park S.H., Han K.D., Oh S., Abdelgawwad K, & Lip G.Y. (2023). Renal outcomes of rivaroxaban compared with warfarin in Asian patients with nonvalvular atrial fibrillation: A nationwide population-based cohort study. Frontiers in Cardiovascular Medicine, 10, 1040834.
Full text: Click here
Publication 2023
Alcoholic Intoxication Antiplatelet Agents Body Weight Cerebrovascular Accident Chronic Kidney Diseases Chronic Obstructive Airway Disease Creatinine Diabetes Mellitus Diagnosis Dietary Modification Dyslipidemias EGFR protein, human Ex-Smokers Heart Failure High Blood Pressures Index, Body Mass Inpatient Kidney Diseases Malignant Neoplasms Myocardial Infarction Outpatients Patients Peripheral Arterial Diseases Pharmaceutical Preparations Self-Examination Serum
5
ST-Elevation Myocardial Infarction Treatment Protocol
In order to be enrolled in this study, subjects must meet the following inclusion criteria: (I) be aged 18–75 years old; (II) meet the diagnostic criteria of the “Guidelines for Primary Diagnosis and Treatment of ST-segment Elevation Myocardial Infarction (2019)” (11 (link)); (III) have received a coronary intervention within 12 hours.
Subjects were excluded from the study if they met any of the following exclusion criteria: (I) had severe heart valve disease, severe congenital heart disease, pulmonary heart disease, or hypertrophic obstructive cardiomyopathy; (II) had liver dysfunction [which was defined as alanine transaminase (ALT) or total bilirubin >3 times the upper normal limit], or renal insufficiency (which was defined as serum creatinine >1.5 times the normal upper limit); (III) were at high risk of bleeding; (IV) had an active peptic ulcer or skin ulcer; (V) were allergic to antiplatelet drugs; (VI) had cardiogenic shock; (VII) had a malignant tumor; (VIII) had a left main lesion as shown by CAG.
Zheng K., Bai J., Xu L, & Chen L. (2023). The value of serum Sema4D level in reflecting the inflammatory state of acute ST-segment elevation myocardial infarction. Journal of Thoracic Disease, 15(2), 627-634.
Publication 2023
Alanine Transaminase Antiplatelet Agents Bilirubin Congenital Heart Defects Cor Pulmonale Creatinine Diagnosis Heart Hypertrophic Obstructive Cardiomyopathy Malignant Neoplasms Peptic Ulcer Renal Insufficiency Serum Shock, Cardiogenic Skin Ulcer ST Segment Elevation Myocardial Infarction Valve Disease, Heart

Top products related to «Antiplatelet Agents»

1
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
2
Teg 5000 thrombelastograph hemostasis analyzer system by Haemonetics
Sourced in United States
The TEG® 5000 Thrombelastograph® Hemostasis Analyzer System is a laboratory instrument used to assess a patient's hemostatic (blood clotting) function. It measures the viscoelastic properties of blood and provides information about the dynamics of clot formation and dissolution.
3
Pfa 100 by Siemens
Sourced in Germany, United States
The PFA-100 is a lab equipment product manufactured by Siemens. It is designed to measure platelet function in blood samples. The device uses a specialized cartridge to analyze the ability of platelets to aggregate in response to specific agonists, providing information about the platelet's activity and function.
4
Vacuette tube by Greiner
Sourced in Austria, Germany, United States, Netherlands
Vacuette tubes are laboratory blood collection tubes designed for the safe and efficient collection of blood samples. They are manufactured to specific standards to ensure consistent quality and performance.
5
Sodium citrate by Terumo
Sourced in Japan, Belgium
Sodium citrate is a sodium salt of citric acid, commonly used as a laboratory reagent. It functions as an anticoagulant, preventing blood from clotting during collection and processing.
6
Dissecting microscope by Nikon
Sourced in Japan, United States
The Nikon Dissecting Microscope is a laboratory instrument designed for the detailed observation and examination of small specimens. It provides a magnified view of the subject, allowing users to study the intricate details and structures. The core function of this microscope is to enable precise and close-up examination of samples, making it a valuable tool in fields such as biology, entomology, and various scientific research applications.
7
Sas statistical software by SAS Institute
Sourced in United States, Austria, Japan, Cameroon
SAS statistical software is a comprehensive data analysis and visualization tool. It provides a wide range of statistical procedures and analytical capabilities for managing, analyzing, and presenting data. The software is designed to handle large and complex datasets, allowing users to perform advanced statistical modeling, regression analysis, and data mining tasks. The core function of the SAS statistical software is to enable users to extract insights and make data-driven decisions.
8
Stata 12 by StataCorp
Sourced in United States, United Kingdom, Denmark, Belgium, Spain, Canada, Austria
Stata 12.0 is a comprehensive statistical software package designed for data analysis, management, and visualization. It provides a wide range of statistical tools and techniques to assist researchers, analysts, and professionals in various fields. Stata 12.0 offers capabilities for tasks such as data manipulation, regression analysis, time-series analysis, and more. The software is available for multiple operating systems.
9
Ticagrelor by Merck Group
Sourced in United States
Ticagrelor is a pharmaceutical product developed by Merck Group. It is a medication used to prevent blood clots and reduce the risk of heart attack or stroke in patients with acute coronary syndrome or a history of myocardial infarction.
10
Au5800 platform by Beckman Coulter
Sourced in United Kingdom
The AU5800 Platform is a fully automated clinical chemistry analyzer developed by Beckman Coulter. It is designed for high-volume clinical laboratories and hospital settings. The AU5800 platform provides automated sample processing, analysis, and result reporting for a variety of clinical chemistry tests.

More about "Antiplatelet Agents"

Antiplatelet drugs, also known as antithrombotic agents, are a class of medications that work by inhibiting platelet aggregation and reducing the risk of thrombosis.
These drugs play a crucial role in the management of various cardiovascular conditions, including coronary artery disease, ischemic stroke, and peripheral artery disease.
Researchers can leverage the power of PubCompare.ai's AI-driven platform to optimize their studies on antiplatelet agents.
This advanced solution allows users to effortlessly locate and compare protocols from literature, pre-prints, and patents, helping to identify the best protocols and products to accelerate their research.
When studying the effects of antiplatelet agents, researchers often utilize various analytical techniques and tools, such as the TEG® 5000 Thrombelastograph® Hemostasis Analyzer System, PFA-100, and SAS version 9.4 statistical software.
These tools can provide valuable insights into platelet function, coagulation, and the overall hemostatic profile of the subjects.
Additionally, the preparation and handling of blood samples, using Vacuette tubes and sodium citrate as an anticoagulant, can be crucial for accurate analysis.
Dissecting microscopes may also be employed to examine platelet morphology and aggregation patterns.
To further enhance their research, researchers may leverage other statistical software, such as Stata 12.0, to analyze the data and draw meaningful conclusions.
Medications like Ticagrelor, a potent antiplatelet agent, are often the focus of these studies, as they play a significant role in the management of cardiovascular diseases.
By utilizing PubCompare.ai's AI-powered platform, researchers can streamline their workflow, identify the most relevant protocols, and accelerate their investigations into antiplatelet agents, ultimately contributing to advancements in cardiovascular care.